LENZ Therapeutics to report Q1 2026 results and highlight progress on May 11, 2026

LENZ Therapeutics will announce its first quarter 2026 financial results and recent corporate highlights in a webcast on May 11, 2026. The company, known for commercializing VIZZ®, the first FDA-approved eye drop for presbyopia, is expanding its global reach with ongoing licensing partnerships. LENZ management will also participate in the Bank of America Global Healthcare Conference in mid-May to engage with investors. This update is important as it reflects LENZ's progress in commercializing a novel treatment for a widespread vision condition affecting millions worldwide.